Kriya Therapeutics raises $270m in Series C funding round
The company intends to use the funds to advance its pipeline and scaling of its platforms.
Cytiva-Cell & Gene Therapy
Latest in
Cytiva-Cell & Gene Therapy
FDA grants Orphan Drug Designation to Editas’ beta thalassemia therapy
The company intends to commence a Phase I/II trial of EDIT-301 in transfusion-dependent beta thalassemia patients this year.
EC approves Novartis’ Kymriah for follicular lymphoma in adults
The EC approval is based on the international Phase II ELARA clinical trial of Kymriah.
Access to CAR-T therapies in Central and Eastern Europe in “catch-up” mode compared to the West
Although some countries are moving ahead, the use of CAR-T therapies in the region remains uneven.
By
FDA grants fast track designation for SQZ’s solid tumour cell therapy
Safety and tolerability will be the primary outcome measures in the monotherapy and combination phases of Phase I/II trial.
Cytovia signs business combination agreement with Isleworth
Current Cytovia co-founder, chairman and CEO Dr Daniel Teper will lead the combined company.
Porton and Sinorda partner to develop cell and gene therapies
Under the deal, Porton will offer services to develop breakthrough cell therapies of Sinorda.
Bluebird bio’s gene therapy Zynteglo could have high price tag defense in beta thalassemia
A $1 million price point is not out of question for bluebird bio’s beta thalassemia therapy if long-term benefits are…
By